TLR8
Toll-like receptor 8
As of the edition of 20 October 2026, TLR8 (toll-like receptor 8, UniProt Q9NR97) has 9 drugs tested at it and 14 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NR97
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 39
- Disease areas
- Cancer; Skin and connective tissue; Immune system; Infections; Digestive system; Urinary and reproductive; Blood and lymph; Lungs and airways
- Registered trials of its drugs
- 63
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Resiquimod | Stopped | Phase 2 | none listed |
| Enpatoran | Active | Phase 3 | none listed |
| Afimetoran | Active | Phase 2 | none listed |
| Motolimod | Stopped | Phase 2 | none listed |
| Selgantolimod | Status not established | Phase 2 | none listed |
| Bazlitoran | Went quiet | Phase 2 | none listed |
| EIK1001 | Active | Phase 3 | none listed |
| INI-4001 | Active | Phase 1 | none listed |
| Telratolimod | Stopped | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Engaged | 8 |
| Undetermined | 2 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Idera Pharmaceuticals | Route A |
| Presage Biosciences | Route A |
The other 11 companies at TLR8
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at TLR8, ranked, with the facts behind eachRequest access. Nothing is shown until you do.